FDA Approves COMBIGAN — Allergan, Inc.

# FDA Approves Allergan's COMBIGAN for Glaucoma Treatment Allergan, Inc. received FDA approval for COMBIGAN (brimonidine tartrate and timolol maleate), an ophthalmic combination therapy designed to reduce intraocular pressure in glaucoma and ocular hypertension patients. The fixed-dose combination positions Allergan to capture market share in the competitive glaucoma treatment segment by offering patients and physicians a convenient dual-agent option that simplifies dosing regimens.